Related references
Note: Only part of the references are listed.Optimizing the outcomes of pancreatic cancer surgery
Oliver Strobel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
Jin-Young Jang et al.
ANNALS OF SURGERY (2018)
Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
Sjors Klompmaker et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail
T. Hank et al.
BRITISH JOURNAL OF SURGERY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
Paula Ghaneh et al.
HEALTH TECHNOLOGY ASSESSMENT (2018)
Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.
Geertjan Van Tienhoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
Thierry Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
Lilian Schwarz et al.
BMC CANCER (2018)
Surgery for Pancreatic Cancer after neoadjuvant treatment
Thilo Hackert
ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)
Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT
Inne Somers et al.
EUROPEAN RADIOLOGY (2017)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Marianne Sinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study
Thilo Hackert et al.
HPB (2017)
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Alok A. Khorana et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
LBA18CONKO-006: A RANDOMIZED DOUBLE-BLINDED PHASE IIB-STUDY OF ADJUVANT THERAPY WITH GEMCITABINE + SORAFENIB/PLACEBO FOR PATIENTS WITH R1-RESECTION OF PANCREATIC CANCER
M. Sinn et al.
ANNALS OF ONCOLOGY (2017)
Pancreatic Cancer Surgery The New R-status Counts
Oliver Strobel et al.
ANNALS OF SURGERY (2017)
Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients
Thilo Hackert et al.
ANNALS OF SURGERY (2016)
Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer
W. Hartwig et al.
BRITISH JOURNAL OF SURGERY (2016)
Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis
Masakatsu Tsurusaki et al.
HEPATOLOGY RESEARCH (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker et al.
LANCET ONCOLOGY (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer
Victoria B. Allen et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Total Pancreatectomy for Primary Pancreatic Neoplasms Renaissance of an Unpopular Operation
Werner Hartwig et al.
ANNALS OF SURGERY (2015)
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
Cristina R. Ferrone et al.
ANNALS OF SURGERY (2015)
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
Riccardo Casadei et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2015)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette Golcher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer
Ryan P. Merkow et al.
ANNALS OF SURGERY (2014)
Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study
Juan W. Valle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
Maximilian Bockhorn et al.
SURGERY (2014)
Imaging diagnosis of pancreatic cancer: A state-of-the-art review
Eun Sun Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial
Fuyuhiko Motoi et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Recent progress in pancreatic cancer
Christopher L. Wolfgang et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
Hemchandra Mahaseth et al.
PANCREAS (2013)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew H. G. Katz et al.
CANCER (2012)
Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
David A. Tuveson et al.
CELL (2012)
Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma
Jan Schmidt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial
William F. Regine et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Stefan Heinrich et al.
BMC CANCER (2011)
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Patrick J. Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Detection of Pancreatic Carcinoma and Liver Metastases with Gadoxetic Acid-enhanced MR Imaging: Comparison with Contrast-enhanced Multi-Detector Row CT
Utaroh Motosugi et al.
RADIOLOGY (2011)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Mark P. Callery et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials
J. P. Neoptolemos et al.
BRITISH JOURNAL OF CANCER (2009)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data
Ross Carter et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The “Artery First” Approach for Resection of Pancreatic Head Cancer
Jürgen Weitz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert et al.
ANNALS OF ONCOLOGY (2008)
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
Asma Sultana et al.
BMC CANCER (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
Matthew H. G. Katz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Adjuvant Chemoradiation for Pancreatic Cancer: Few Good Data, Much Debate
Renee Twombly
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
C. M. Halloran et al.
BRITISH JOURNAL OF SURGERY (2008)
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation - Long-term results of EORTC trial 40891
Hans G. Smeenk et al.
ANNALS OF SURGERY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy
Gauri R. Varadhachary et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial
C Bassi et al.
DIGESTIVE SURGERY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma
T Takada et al.
CANCER (2002)
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial
JP Neoptolemos et al.
LANCET (2001)
Share Paper
